Skip to main content
OpenTrials
Completed

NCT Number: NCT07020949

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM

The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with T2DM. This study includes three multiple-ascending dose cohorts.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Peking University First Hospital

Beijing, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients 18 to 75 years of age, inclusive;
  • Have T2DM for at least 6 months before screening based on the disease diagnostic criteria (World Health Organization [WHO] Classification for Diabetes);
  • Treated with diet and exercise alone, or a stable dose of metformin (≥1000 mg/day and not more than the locally approved dose) for at least 2 months prior to screening;
  • Have a BMI between 23 and 35 kg/m²(inclusive) at screening;
  • HbA1c levels: 7.0% to 10.0% (inclusive) for subjects treated by diet or exercise alone; 7.0% to 9.0% (inclusive) for subjects receiving stable-dose metformin.

Exclusion criteria

  • Have been diagnosed with proliferative diabetic retinopathy, diabetic maculopathy, or non-proliferative diabetic retinopathy requiring treatment during the study;
  • Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia type 2;
  • Have diagnosed hyperthyroidism or hypothyroidism;
  • Have grade 2 hypoglycemia events or grade 3 hypoglycemia events within 6 months prior to screening;
  • Have a history of ketoacidosis, lactic acidosis, or hyperosmolar state leading to hospitalization within 6 months prior to screening;
  • Presence of uncontrolled hypertension at screening: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg;
  • Prolonged QTcF interval on 12-lead ECG at screening (QTcF≥450 ms for males, >470 ms for females), PR interval >200 ms, or the presence of long QT syndrome, second- or third-degree atrioventricular block, left or right bundle branch block, Wolff-Parkinson-White syndrome, or any other clinically significant arrhythmias (except sinus arrhythmia);
  • Weight change ≥ 5% within 3 months prior to screening;
  • Have been treated with insulin, excluding insulin therapy for gestational diabetes mellitus, or acute/temporary insulin therapy (≤ 14 days) for conditions such as acute illness, hospitalization, or elective surgery.

Treatment and study plan

THDBH120 injection

Drug

Participants received THDBH120 by subcutaneous injection.

Placebo of THDBH120 injection

Drug

Participants received placebo by subcutaneous injection.

Primary outcomes

  1. Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)

    Time frame: 78 days

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of THDBH120.

    Time frame: Day 1 Pre-dose through Day 43

  2. Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of THDBH120

    Time frame: Day 1 Pre-dose through Day 43

  3. Change From Baseline in HbA1C

    Time frame: 43 days

  4. Number of Participants With Anti-THBHD120 Antibodies

    Time frame: 78 days

Sponsors and collaborators

Lead sponsor

Tonghua Dongbao Pharmaceutical Co.,Ltd

Industry

Registry information

Official study title

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM: A Randomized, Bouble-Blind, Placebo-Controlled Phase Ib Trial

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jun 13, 2025
Registry last updated
Jun 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.